+19.9%
MDT vs MRNA
+945.0%
-925.1%
-28.9%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 1y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | +6.1% | +13.1% | -7.0% | +5.9% |
| 7D | +10.7% | +20.6% | -9.9% | +10.4% |
| 30D | +19.3% | +27.1% | -7.8% | +18.7% |
| 3M | +22.8% | +353.4% | -330.6% | +17.3% |
| 6M | +36.4% | +446.3% | -409.9% | +27.8% |
| YTD | +12.1% | +776.2% | -764.1% | +0.8% |
| 1Y | +19.9% | +987.9% | -968.0% | +3.4% |
| All | +19.9% | +945.0% | -925.1% | +3.4% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 1y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
1y analysis · Full analysis span regression · 6 months rolling